Massachusetts Financial Services Co. MA Makes New $199.18 Million Investment in Repligen Corporation $RGEN

Key Points

• Massachusetts Financial Services Co. MA acquired 1,215,527 shares of Repligen in Q4 valued at approximately $199.18 million, representing a 2.16% stake in the company.
• Several other large funds likewise initiated or increased positions—leaving institutional investors and hedge funds with about 97.64% of Repligen's shares outstanding.
• Repligen beat Q4 EPS and revenue estimates (EPS $0.49; revenue $197.9M, +18.1% YoY), set FY2026 EPS guidance of 1.93–2.01, and carries a sell‑side consensus of Moderate Buy with a $176.92 target price.

Massachusetts Financial Services Co. MA acquired a new position in Repligen Corporation (NASDAQ:RGEN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,215,527 shares of the biotechnology company's stock, valued at approximately $199,176,000. Massachusetts Financial Services Co. MA owned 2.16% of Repligen as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of RGEN. United Capital Financial Advisors LLC acquired a new position in shares of Repligen in the third quarter worth about $368,387,000. Balyasny Asset Management L.P. raised its position in shares of Repligen by 390.6% in the third quarter. Balyasny Asset Management L.P. now owns 767,239 shares of the biotechnology company's stock worth $102,557,000 after acquiring an additional 610,837 shares during the period. Congress Asset Management Co. increased its stake in shares of Repligen by 241.4% during the fourth quarter. Congress Asset Management Co. now owns 746,306 shares of the biotechnology company's stock worth $122,290,000 after purchasing an additional 527,714 shares in the last quarter. Holocene Advisors LP increased its stake in shares of Repligen by 47.0% during the third quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company's stock worth $184,077,000 after purchasing an additional 440,290 shares in the last quarter. Finally, Vestal Point Capital LP purchased a new stake in shares of Repligen during the third quarter worth about $53,468,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on RGEN shares. Barclays cut their target price on shares of Repligen from $200.00 to $175.00 and set an "overweight" rating for the company in a research note on Wednesday, February 25th. HC Wainwright boosted their target price on shares of Repligen from $180.00 to $208.00 and gave the stock a "buy" rating in a research note on Monday, March 23rd. Wells Fargo & Company cut their target price on shares of Repligen from $190.00 to $180.00 and set an "overweight" rating for the company in a research note on Wednesday, February 25th. KeyCorp reissued an "overweight" rating on shares of Repligen in a research note on Wednesday, February 25th. Finally, Wall Street Zen cut shares of Repligen from a "buy" rating to a "hold" rating in a research note on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and a consensus target price of $176.92.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $120.10 on Monday. Repligen Corporation has a 12-month low of $109.66 and a 12-month high of $175.77. The stock has a market cap of $6.77 billion, a PE ratio of 141.29, a P/E/G ratio of 2.35 and a beta of 1.19. The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. The company has a 50-day moving average of $126.35 and a 200 day moving average of $146.45.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The company had revenue of $197.91 million during the quarter, compared to analysts' expectations of $192.23 million. During the same quarter in the prior year, the company earned $0.44 EPS. Repligen's revenue was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, sell-side analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

About Repligen

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.